Thromb Haemost 1981; 46(03): 638-641
DOI: 10.1055/s-0038-1653436
Original Article
Schattauer GmbH Stuttgart

Activated Factor IX Complex in Treatment of Surgical Cases of Hemophilia A with Inhibitors

Wahid T Hanna
1   The Hematology-Oncology Section, Department of Medical Biology, Memorial Research Center of The University of Tennessee College of Medicine/Knoxville Units, U.S.A
,
Robert R Madigan
1   The Hematology-Oncology Section, Department of Medical Biology, Memorial Research Center of The University of Tennessee College of Medicine/Knoxville Units, U.S.A
,
Marian A Miles
1   The Hematology-Oncology Section, Department of Medical Biology, Memorial Research Center of The University of Tennessee College of Medicine/Knoxville Units, U.S.A
,
Robert D Lange
1   The Hematology-Oncology Section, Department of Medical Biology, Memorial Research Center of The University of Tennessee College of Medicine/Knoxville Units, U.S.A
› Author Affiliations
Further Information

Publication History

Received 02 March 1981

Accepted 10 August 1981

Publication Date:
05 July 2018 (online)

Preview

Summary

Three patients with severe hemophilia A with inhibitors to factor VIII were treated with activated factor IX complex. Bleeiling was controlled adequately during surgical procedures involving each of the three. Partial thromboplastin times showed a variable shortening and prothrombin times were significantly shortened to values less than normal. Hemostasis was substantiated by the use of epsilon aminocaproic acid. Neither anamnestic responses nor thrombotic complications were observed. A transient hypertension developed in two patients shortly after infusion with the activated factor IX complex.